Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
NCT03507374 · University of Utah · EARLY_PHASE1 · terminated · last registry update 2020-04-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding withdrawn” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-01Results posted on the registry: Columbia University, Evolocumab (NCT03331666)
- 2021-04-01Also stopped (terminated): Columbia University, Evolocumab (NCT03331666)
- 2021-03-19Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Background lipid lowering therapy (NCT04807400)
- 2021-03-19Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04806893)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797104)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04798430)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797247)
- 2021-03-10Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep + evolocumab (NCT04790513)
- 2021-02-21Phase 3 first posted: Novartis Pharmaceuticals, inclisiran sodium + Placebo (NCT04765657)
- 2020-12-29Results posted on the registry: Sanofi, Alirocumab SAR236553 (REGN727) + Atorvastatin (NCT03510715)
- 2020-12-14Phase 3 first posted: Hamid Al-Essa Organ Transplant Center, Evolocumab (NCT04665830)
- 2020-12-09Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Placebo (NCT04659863)
- 2020-12-03Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Placebo (NCT04652726)
- 2020-11-03Results posted on the registry: Amgen, evolocumab (NCT03403374)
- 2020-10-28Results posted on the registry: The Medicines Company, Inclisiran + Placebo (NCT03397121)
- 2020-10-14Also stopped (withdrawn): Copenhagen University Hospital, Rigshospitalet, Evolocumab or Alirocumab (NCT02941016)
- 2020-10-05Results posted on the registry: The Medicines Company, Inclisiran Sodium + Placebo (NCT03399370)
- 2020-08-21Results posted on the registry: The Medicines Company, Inclisiran Sodium + Placebo (NCT03400800)
- 2020-08-05Results posted on the registry: Regeneron Pharmaceuticals, Alirocumab + Placebo Matched to Alirocumab (NCT01576484)
- 2020-07-24Results posted on the registry: Johns Hopkins University, Evolocumab (NCT03500302)
- 2020-07-21Results posted on the registry: Amgen, Evolocumab + Placebo (NCT02833844)
- 2020-07-15Results posted on the registry: Amgen, Evolocumab + Placebo (NCT02392559)
- 2020-06-17Results posted on the registry: Regeneron Pharmaceuticals, Alirocumab + Placebo (NCT01604824)
- 2020-05-18Results posted on the registry: The Medicines Company, ALN-PCSSC + Standard of Care (NCT02963311)
- 2020-05-01Results posted on the registry: Regeneron Pharmaceuticals, Placebo + Alirocumab (NCT02326220)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision